Mitochondrial transcript maturation and its disorders by Van Haute L et al.
SSIEM 2014
Mitochondrial transcript maturation and its disorders
Lindsey Van Haute
1
& Sarah F. Pearce
1
& Christopher A. Powell
1
&
Aaron R. D’Souza1 & Thomas J. Nicholls1,2 & Michal Minczuk1
Received: 17 February 2015 /Revised: 27 April 2015 /Accepted: 29 April 2015 /Published online: 28 May 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Mitochondrial respiratory chain deficiencies exhib-
it a wide spectrum of clinical presentations owing to defective
mitochondrial energy production through oxidative phosphor-
ylation. These defects can be caused by either mutations in the
mitochondrial DNA (mtDNA) or mutations in nuclear genes
coding for mitochondrially-targeted proteins. The underlying
pathomechanisms can affect numerous pathways involved in
mitochondrial biology including expression of mtDNA-
encoded genes. Expression of the mitochondrial genes is ex-
tensively regulated at the post-transcriptional stage and entails
nucleolytic cleavage of precursor RNAs, RNA nucleotide
modifications, RNA polyadenylation, RNA quality and stabil-
ity control. These processes ensure proper mitochondrial
RNA (mtRNA) function, and are regulated by dedicated,
nuclear-encoded enzymes. Recent growing evidence suggests
that mutations in these nuclear genes, leading to incorrect
maturation of RNAs, are a cause of human mitochondrial
disease. Additionally, mutations in mtDNA-encoded genes
may also affect RNAmaturation and are frequently associated
with human disease. We review the current knowledge on a
subset of nuclear-encoded genes coding for proteins involved
in mitochondrial RNA maturation, for which genetic variants
impacting upon mitochondrial pathophysiology have been
reported. Also, primary pathological mtDNA mutations with
recognised effects upon RNA processing are described.
Introduction
Mitochondria are cellular compartments present in every cell
of the human body (except red blood cells) and are responsible
for generating almost all of the energy needed to sustain life
and to grow. In mitochondria, energy is produced in the pro-
cess of oxidative phosphorylation (OXPHOS). The biogenesis
of the OXPHOS system entails assembly of approximately 90
proteins into five complexes. Most of these proteins are
encoded by DNA that is contained within the cell nucleus
(nDNA). However, 13 of these are encoded within a small,
circular genome inside mitochondria (Fig. 1). Recent research
has identified defects in mitochondrial DNA (mtDNA) ex-
pression that are associated with a diverse group of human
disorders characterised by impaired mitochondrial respiration
(Nicholls et al 2013; Boczonadi and Horvath 2014). Many
regulatory factors and pathways are involved in mitochondrial
gene expression and establishing the molecular details of how
defects in these processes contribute to human disease consti-
tutes a major challenge.
In addition to messenger RNAs (mt-mRNAs), the human
mitochondrial transcriptome also consists of two ribosomal
RNAs (mt-rRNAs, 12S and 16S) that are a part of the mito-
chondrial ribosome and a complete set of 22 transfer RNAs
(mt-tRNAs) (Rorbach and Minczuk 2012) (Fig. 1). All of the
mitochondrial protein factors necessary for RNA synthesis,
endonucleolytic processing, post-transcriptional modifica-
tions, aminoacylation, RNA stability regulation, and RNA
turnover along with the factors necessary for biogenesis of
the mitochondrial ribosome and translation are encoded by
nDNA and imported to mitochondria upon translation in the
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cytosol. Based on the literature, evidence from studies of hu-
man mitochondrial proteomes (Pagliarini et al 2008; Smith
et al 2012) and our unpublished predictions, we estimate that
250–300 nuclear-encoded proteins are dedicated to serve mi-
tochondrial gene expression.
Mutations associated with mitochondrial disease are locat-
ed either within nDNA or mtDNA. Most mitochondrial dis-
eases are early onset, multi-systemic (affecting the brain,
heart, skeletal muscle, liver and other organs) and often fatal.
Inherited pathological mutations in genes encoding compo-
nents involved in mitochondrial gene expression are generally
associated with combined OXPHOS deficiencies affecting
multiple enzymes involved in cellular respiration. However,
isolated OXPHOS deficiencies, that affect only a specific bio-
chemical activity of the OXPHOS system, have also been
described for mutants in mitochondrial gene expression (e.g.
Haack et al 2013). Many pathological mutations in the
mtDNA-encoded tRNAs and rRNAs have been identified
thus far (Yarham et al 2010), and given the size of mtDNA,
detection of yet uncharacterised mutations is relatively
straightforward. In contrast, the molecular diagnosis of pa-
tients with defects of mitochondrial gene expression due to
mutations in nDNA is particularly difficult, mostly because
of the high number of nuclear genes involved in these process-
es with only a fraction of them being characterised to date
(Nicholls et al 2013; Boczonadi and Horvath 2014).
This review article describes how defects in mitochondrial
RNA maturation are linked to human mitochondrial disease.
We provide an overview of the mechanisms of mitochondrial
transcript synthesis, endonucleolytic processing and post-
transcriptional modifications of each class of mtRNA. This
is followed by a description of a subset of nuclear-encoded
factors involved in mtRNA metabolism, for which genetic
variants impacting upon mitochondrial pathophysiology have
been reported. Finally, we discuss primary pathological
mtDNA mutations with recognised effects upon mt-tRNA
nucleolytic processing and post-transcriptional maturation.
Mechanisms of mitochondrial RNA maturation
The generation of functional RNA molecules used for protein
synthesis requires transcription, nucleolytic processing, post-
transcriptional nucleotide modifications, polyadenylation of
mt-mRNA andmt-tRNA-aminoacylation (Fig. 2). These steps
are coordinated with RNA quality control, RNA stability reg-
ulation, biogenesis of the mitochondrial ribosome and trans-
lation activation (Fig. 2). However, the mechanistic details of
how these processes occur are still unknown. In the first part
of the review, before discussing human diseases associated
with defects of mitochondrial RNA metabolism, we summa-
rise the current available data on mtRNA metabolism.
Generation of primary transcript and its endonucleolytic
processing
Mitochondrial transcription
Transcription of the human mitochondrial genome occurs on
both DNA strands, is polycistronic, and produces long tran-
scripts of mt-mRNAs and mt-rRNAs, usually interspersed
with mt-tRNAs (Ojala et al 1981). Transcription of the light
strand (L-strand, Fig. 1) template occurs from a single pro-
moter (L-strand promoter, LSP) and this long transcript en-
codes the ND6 gene and eight mt-tRNAs (Figs. 1 and 3)
(Montoya et al 1982, 1983). The majority of initiation events
from LSP are believed to terminate some 200 bases down-
stream from the promoter, at Bconserved sequence block 2^
(CSB2) (Wanrooij et al 2010). This short RNA species is used
to prime replication of the heavy DNA strand (H-strand,
Fig. 1) as well as the synthesis of the D-loop, whose biogen-
esis and function is discussed in our recent review (Nicholls
and Minczuk 2014). Classically, transcription of the H-strand
template is initiated from two sites (H-strand promoter 1 and
2, HSP1 and HSP2), located approximately 100 bases apart in
the non-coding region (NCR) (Montoya et al 1982, 1983;
Chang and Clayton 1984). HSP1 is located just upstream of
the mt-tRNAPhe gene, and initiation from this site produces a
short transcript consisting of the two ribosomal RNAs (12S
and 16S) and mt-tRNAVal , terminating at the mt-
tRNALeu(UUR) gene. Transcription from HSP2, immediately
upstream from the 12S mt-rRNA gene, bypasses this
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Fig. 1 Genetic map of the mitochondrial genome. The organisation of
the genes on human mitochondrial genome is shown. The two strands of
the human mtDNA, denoted light (L-) and heavy (H-), code for 2 mt-
rRNAs (blue), 22 mt-tRNAs (green) and 11 mt-mRNA molecules (red).
The 11mt-mRNAs encode 13 polypeptides of the electron transport chain
and ATP synthase, where open reading frames of ATP8/ATP6 and ND4/
ND4L overlap and are contained within bicistronic mRNAs. The main
non-coding region (NCR) contains promoters for transcription of the H-
strand and L-strand, HSP and LSP, respectively
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termination and produces an almost genome-length transcript
of 2 mt-rRNAs, 12 mt-mRNAs and 14 mt-tRNAs. The mito-
chondrial transcription termination factor mTERF1 binds
strongly to a tridecamer DNA sequence and has been pro-
posed to terminate H-strand transcription at the mt-
tRNALeu(UUR) gene (Christianson and Clayton 1988; Kruse
et al 1989; Fernandez-Silva et al 1997). However, this was
brought into doubt by the discovery that a mouse knockout
of mTERF1 had normal H-strand transcription (Terzioglu et al
2013). It has been suggested that mTERF1 may actually serve
to terminate the L-strand transcript, preventing the formation
of antisense mt-rRNA species. The existence of HSP2 as a
functional promoter in vivo is also questionable as transcrip-
tion from this site is not readily detectable using established
in vitro transcription systems (Litonin et al 2010). It may be
the case, therefore, that only LSP and HSP1 (indicated as HSP
on Fig. 1) are responsible for the transcription of all
mitochondrially-encoded transcripts.
The basal protein machinery necessary for mitochondrial
transcription has been well studied in humans, where RNA
synthesis is performed by a single-subunit mitochondrial
RNA polymerase, POLRMT, that shares homology with the
RNA polymerases of the T-odd phages T3 and T7 (Masters
et al 1987). POLRMT was identified through its homology
with its yeast counterpart (Tiranti et al 1997). Later two ho-
mologues of the yeast mitochondrial transcription factor,
mtTFB, were identified and named TFB1M and TFB2M
(Falkenberg et al 2002; Cotney and Shadel 2006). Both con-
tain an rRNA methyltransferase-like fold (Shutt and Gray
2006). TFB2M has been found to be necessary for transcrip-
tion, and so appears to be the functional homologue of yeast
mtTFB (Falkenberg et al 2002; Litonin et al 2010). TFB1M,
on the other hand, appears to have mainly retained its
dimethyltransferase function (see below) (Seidel-Rogol et al
2003; Metodiev et al 2009). Transcription in human mito-
chondria also requires mitochondrial transcription factor A
(TFAM) (Falkenberg et al 2002; Shi et al 2012). The ability
of TFAM to activate transcription is dependent upon a C-
terminal tail, which is absent from its yeast homologue,
Abf2p (Dairaghi et al 1995; Garstka et al 2003). Consistent
with this, Abf2p is not required for yeast mitochondrial tran-
scription, and is only involved in DNA packaging (Diffley
and Stillman 1991; Parisi et al 1993).
In addition to these core factors, other proteins implicated
in mitochondrial transcription include the transcription elon-
gation factor TEFM and the large mitoribosomal subunit
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Fig. 2 Mitochondrial RNA
metabolism. The mitochondrial
rRNAs (blue), mRNAs (red) and
tRNAs (green) are transcribed
from the L- and H-strands as
polycistronic units that undergo
endonucleolytic processing.
Following the liberation of the
individual mt-mRNA, mt-rRNA
and mt-tRNA transcripts, they
undergo post-transcriptional
modifications. Several
nucleotides of mt-rRNAs are
modified to facilitate
mitoribosome biogenesis and
function. A poly(A) tail is added
to mt-mRNAs, with the exception
of the L-strand-encoded ND6.
Mt-tRNAs undergo extensive
post-transcriptional nucleotide
modification, in addition to a
CCA trinucleotide synthesis at the
3′ end, before being
aminoacylated with a cognate
amino acid. Decay and
surveillance pathways have also
been described for mammalian
mtRNA
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protein MRPL12. Acting in complex with POLRMT, TEFM
is necessary for processivity of the polymerase and for in-
creasing transcription rates by preventing a termination event
at CSB2 (Minczuk et al 2011; Agaronyan et al 2015; Posse
et al 2015). MRPL12 has also been found to bind POLRMT,
and stimulate transcription in in vitro reactions (Wang et al
2007). This stimulatory effect was not observed in a later
study from another group (Litonin et al 2010).
Nucleolytic processing of mitochondrial precursor RNA
Transcription of mtDNA results in polycistronic RNA mole-
cules (Fig. 3). Most of the mt-mRNA or mt-rRNA-coding
regions are separated by mt-tRNAs, which upon excision gen-
erate RNA products for translation or assembly into ribosomes
(Anderson et al 1981; Ojala et al 1981). This processingmech-
anism is referred to as the ‘tRNA punctuation model’. RNase
P and RNase Z (elaC homolog 2 (ELAC2)) are the two main
factors involved in mt-tRNA excision.
The RNase P enzyme is responsible for the 5′ end endonu-
cleolytic cleavage of mt-tRNA precursors. Unlike the previ-
ously characterised RNase P enzymes, the mitochondrial
counterpart contains no catalytic RNA component. Instead,
it is composed of three multifunctional mitochondrial RNase
P proteins, MRPP1 (TMRT10C or RG9MTD1), MRPP2
(HSD17B10, SDR5C1) and MRPP3 (Holzmann et al 2008).
MRPP1 is a m1G9-methylase, whereas MRPP2 is a dehydro-
genase also involved in isoleucine metabolism and other cel-
lular functions (Yang et al 2005). MRPP1 and MRPP2 form a
subcomplex that also participates in mt-tRNA modification
(Vilardo et al 2012) (see below). MRPP3 is responsible for
hydrolysis of the RNA phosphodiester bond (Rossmanith and
Holzmann 2009). Knockdown of the different protein compo-
nents of the mitochondrial RNase P all cause an accumulation
of precursor RNA molecules (Holzmann et al 2008). Also,
MRPP1 or MRPP3 knockdown reduced steady state levels
of mature mt-tRNAs and some mt-mRNAs, which had a det-
rimental effect on mitochondrial translation (Sanchez et al
2011).
RNase Z, encoded byELAC2, is an endonuclease that com-
pletes the excision of mt-tRNAs from the primary transcript at
the 3′ end. Human ELAC2 has been identified by homology
to the bacterial counterpart elaC. There are two human genes
encoding orthologs of elaC: ELAC1 and ELAC2. ELAC1
encodes a short form of RNase Z, localised in the cytosol
(Rossmanith 2011), whereas ELAC2 encodes a long
form of RNase Z and is restricted to eukaryotes.
Alternative translation initiation of ELAC2 mRNA gen-
erates two products, of which only the longer form lo-
calises to mitochondria. In vitro, ELAC2 shows catalytic
activity on both nuclear and mitochondrial pre-tRNAs
(Rossmanith 2011). Knockdown of the protein causes
the accumulation of mt-tRNA precursors (Brzezniak
et al 2011; Sanchez et al 2011).
Other proteins have been recently implicated in precursor
RNA processing in mitochondria. G-rich sequence factor 1,
GRSF1, is an RNA-binding protein that co-localises with
newly synthesised transcripts in mitochondrial foci named
BRNA granules^ (Antonicka et al 2013; Jourdain et al
2013). A decrease in some mature mitochondrial transcripts
upon GRSF1 knockdown and co-localisation of GRSF1 with
MRPP1 in RNA granules suggested a possible cooperative
role in precursor RNA processing (Jourdain et al 2013). The
discovery of RNA granules has catalysed further research on
these structures, indicating very recently that they are central
for post-transcriptional RNAmaturation and the biogenesis of
mitochondrial ribosomes (see below) (Antonicka and
Shoubridge 2015; Jourdain et al 2015).
Pentatricopeptide-repeat containing (PPR) domain family
of proteins member 1, PTCD1 (Small and Peeters 2000), is
predicted to have a role in mtRNA metabolism. It has been
suggested that this protein plays a role in coordinating 3′
Fig. 3 Polycistronic transcription units in mitochondria. Polycistronic
precursor mitochondrial transcripts are shown. The transcript from LSP
contains only the coding sequences for the ND6 subunit of complex I and
eight mt-tRNAs. All other coding sequences are produced by
transcription from HSP. With some exceptions (triangles), mt-rRNAs
(blue) and mt-mRNAs (red) are punctuated with mt-tRNAs (green).
The endonucleolytic processing of mt-tRNA liberates most of the mt-
mRNAs and the two mt-rRNAs. The enzymatic machinery responsible
for the processing at the non-canonical sites, not punctuated with mt-
tRNAs, is not well investigated. ND6 mRNA shows multiple 3′ ends:
either 500 nt (Slomovic et al 2005) or 30 nt (Mercer et al 2011) down-
stream of the translation termination codon
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processing of mt-tRNAs and that there is a direct interaction
between PTCD1 and ELAC2 (Sanchez et al 2011). Additional
studies have suggested a role for PTCD1 in controlling the
levels of both leucine mt-tRNAs (Rackham et al 2009), which
might have a role in adaptation of mitochondria to amino acid
starvation (Schild et al 2014).
There are various sites in mitochondrial polycistronic tran-
scripts that are not consistent with the ‘tRNA punctuation
model’ and are cleaved independently of the presence of mt-
tRNAs (Fig. 3). These include: (i) the bicistronic ATP8/6-
COIII, (ii) the 5′ end of COI, (iii) the 5′ end of CytB, and
(iv) the 3′ end of ND6 (Anderson et al 1981; Temperley et al
2010). There are no obvious sequence motifs within the prox-
imal regions of COI, COIII or CytB that could serve as rec-
ognition sites for cleavage. Knockdown of ELAC2 and the
components of RNase P show no effect on the levels of these
non-conventional cleavage sites (Brzezniak et al 2011).
PTCD2 has been implicated in the cleavage of the junction
between ND5 and CytB (Fig. 3) as a PTCD2 knockout mouse
accumulates the ND5-CytB precursor and do not properly
assemble complex III (where CytB is the catalytic core com-
ponent) (Xu et al 2008a). More recently, an RNA granule
protein, FASTKD5 (Fas-activated serine/threonine (FAST) ki-
nase domain containing protein 5), has been suggested to be
required for maturing precursor of COI mRNA (Antonicka
and Shoubridge 2015). However, the exact role of these pro-
teins in relation to mtRNA endonucleolytic processing re-
mains to be determined.
Mitochondrial mRNA maturation and maintenance
Mitochondrial mRNA polyadenylation
Mitochondrial mRNAs liberated by mt-tRNA excision under-
go further maturation steps, however, the scope of these events
is very limited when compared to the nuclear-encoded mRNAs.
Mitochondrialmt-mRNAs do not contain the 5′ capmodification
nor introns to be spliced. Most mt-mRNAs are polyadenylated
on their 3′ ends, with poly(A) tails being much shorter (approx-
imately 45–55 nt) than the ones found on the nDNA-encoded
mRNAs. Poly(A) tails have not been detected in the case of ND6
mt-mRNA and the ND5 transcript is oligoadenylated (or not
adenylated at all) (Temperley et al 2010).
Mitochondrial poly(A) tails are synthesised by a non-
canonical poly(A) polymerase (mtPAP) that localises to the
mitochondrial RNA granules (Tomecki et al 2004; Nagaike
et al 2005; Bai et al 2011; Wilson et al 2014). Knockdown of
mtPAP causes shortening of poly(A) tails and disruption of the
respiratory function (Nagaike et al 2005). Although mtPAP
can use all four nucleoside triphosphates (NTPs) as substrates,
it is most active with ATP (Bai et al 2011).
Phosphodiesterase 12 (PDE12), a mitochondrial 2′- and 3′-
phosphodiesterase (Poulsen et al 2011; Rorbach et al 2011),
has been shown to specifically remove poly(A) tails from mt-
mRNAs in vitro and in cultured cells upon overexpression
(Rorbach et al 2011). The 3′-to-5′ deadenylase activity of
PDE12 requires a free 3′-OH group and prefers homopoly-
mers of adenines.
The exact role for mitochondrial poly(A) tails is still un-
clear (Rorbach et al 2014a). However, seven out of 13
mtDNA-derived ORFs do not encode complete stop codons
for the termination of translation. In these cases, the mt-
mRNAs are immediately adjacent to mt-tRNA genes and the
excision of mt-tRNA leaves behind an incomplete stop codon
of ‘U’ or ‘UA’ (Anderson et al 1981). Polyadenylation gener-
ates a complete ‘UAA’ stop codon (Ojala et al 1981).
Polyadenylation has different effects on the stability of var-
ious mitochondrial transcripts. It generally decreases the sta-
bility of COI, COII, COIII and ATP6/8, and increases the
stability of ND1 and ND2. Polyadenylation also causes the
increase in stability of ND3, ND4/4 L, ND5 and CytB to a
lesser extent (Rorbach et al 2011; Wydro et al 2010; Rorbach
andMinczuk 2012). The mechanism of this transcript-specific
role of polyadenylation remains to be elucidated.
Whether poly(A) tail addition is directly involved in regu-
lating mitochondrial translation in the mitochondria is still an
unresolved issue. Overexpression of mitochondrial
deadenylase PDE12 or mitochondrially targeted cytosolic
poly(A)-specific ribonuclease (PARN) caused strong inhibi-
tion of protein synthesis. This is further supported by the ob-
servation that targeting cytosolic poly(A)-binding protein 1
(PABPC1) into the mitochondria inhibited translation
(Wydro et al 2010). However, inactivation of mitochondrial
protein LRPPRC (see the next section) in a mouse knockout
model or loss-of-function mutations in MTPAP (Wilson et al
2014) (described below) were associated with the loss of mt-
mRNA poly(A) tails with no universal effect on translation.
The latter result suggests that translation of some mitochon-
drial transcripts can be effective even in the absence of mt-
mRNA polyadenylation.
Mitochondrial mRNA stability, decay and surveillance
Regulation of RNA stability and turnover are important steps
in post-transcriptional control of gene expression and are usu-
ally mediated by protein complexes. Several proteins have
been implicated in these processes in human mitochondria.
The human Suv3 protein (hSuv3p, Suppressor of Var1, 3-
like protein 1, SUPV3L1) is an NTP-dependent helicase that
localises to the mitochondria. The SUPV3L1 gene undergoes
alternative splicing and contains more than one translation
initiation site, the latter observed for a number of
mitochondrially-targeted proteins (Minczuk et al 2005;
Szczesny et al 2007; Kazak et al 2013). At least one of the
isoforms localises to the mitochondrial matrix (Minczuk et al
2002). hSuv3p is able to unwind multiple DNA and RNA
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substrates (Minczuk et al 2002; Shu et al 2004). It has been
suggested that hSuv3p is involved in mtRNA degradation of
aberrant mtRNA (Khidr et al 2008; Szczesny et al 2010) and
plays a role in the decay pathway of properly processed RNA
molecules (Szczesny et al 2010).
Polynucleotide phosphorylase, PNPase (encoded by
PNPT1), is capable of 3′-to-5′ phosphorolysis and 5′-to-3′
polymerisation of RNA (Wang et al 2009). PNPase has been
reported to form complexes localised in the matrix, although
mitochondrial inner membrane space localisation has also
been observed (Chen et al 2006). PNPase has been attributed
to numerous roles in mtRNA metabolism, including degrada-
tion, polyadenylation and RNA import (Chen et al 2006;
Slomovic and Schuster 2008; Borowski et al 2013; Chujo
et al 2012).
Recent evidence indicates that PNPase co-localises with
hSuv3p in the mitochondria in distinctive RNA-positive foci
and works in collaboration to facilitate RNA degradation
(Szczesny et al 2010). This suggests that there might be two
pools of PNPase, in the intermembrane space and in the matrix
(Borowski et al 2013). In vitro reconstitution experiments
have indicated that the hSuv3-PNPase complex degrades
RNA substrates in the 3′-to-5′ direction (Wang et al 2009;
Lin et al 2012).
The RNA exonuclease 2, REXO2, is an additional mito-
chondrial nuclease potentially involved in mtRNA metabo-
lism. It is a homotetrameric 3′-to-5′ exonuclease that degrades
oligonucleotides and is localised to both the intermembrane
space and the matrix (Bruni et al 2013). Given that the
PNPase-hSuv3p complex is expected to degrade RNA pro-
ducing oligo-ribonucleotides, it is possible that they form the
substrate of REXO2 for later stages of the decay pathway.
REXO2 has also been proposed to have a function in
recycling mono-ribonucleotides (Bruni et al 2013).
RNA-binding proteins are often key regulators of the post-
transcriptional life of transcripts. Two mitochondrial RNA-
binding proteins, LRPPRC and SLIRP, have been recently
associated with mtRNA metabolism. LRPPRC is a highly
abundant 130 kDa leucine-rich PPR containing protein, and
is predominately localised in the mitochondrial matrix (Sterky
et al 2010). Inactivation of LRPPRC results in a severe deple-
tion of mt-mRNA, but not mt-rRNA or mt-tRNA, and a con-
sequential impairment in translation and in assembly of
mitochondrially-encoded OXPHOS subunits (Gohil et al
2010; Sasarman et al 2010a; Sondheimer et al 2010;
Ruzzenente et al 2012; Mourier et al 2014). Stem-loop
interacting RNA binding protein, SLIRP, is essential for mt-
RNA maintenance (Baughman et al 2009) and exists in a
high-molecular-weight complex with LRPPRC (Sasarman
et al 2010b). The LRPPRC-SLIRP complex regulates mt-
mRNA stability and translation without directly associating
with ribosomes or POLRMT (Ruzzenente et al 2012;
Harmel et al 2013). Knockdown of one of the two proteins
caused a decrease in endogenous levels of the other, suggest-
ing strong interdependence (Chujo et al 2012; Ruzzenente
et al 2012). The LRPPRC-SLIRP complex has been recently
associated with a role in mt-mRNA polyadenylation.
Inactivation of either LRPPRC or SLIRP resulted in a reduc-
tion in polyadenylated mt-mRNAs, with an in vitro stimula-
tory effect of LRPPRC-SLIRP, but not SLIRP alone, on
polyadenylation by mtPAP (Chujo et al 2012; Wilson et al
2014). It has been suggested that LRPPRC plays a role in
stabilising a pool of translationally-inactive mt-mRNAs that
are not associated with ribosomes (Ruzzenente et al 2012).
The LRPPRC-SLIRP complex may also function by binding
to the mt-mRNA and preventing the formation of secondary
s t ructures making the 3 ′ - te rmina l ava i lab le for
polyadenylation. This activity of the complex might also be
involved in suppressing PNPase-hSuv3-mediated mt-mRNA
degradation (Chujo et al 2012).
Mitochondrial rRNA maturation
Human mitochondrial ribosomes are composed of two un-
equally sized subunits (Brown et al 2014; Greber et al 2014;
Kaushal et al 2014; Amunts et al 2015). The small 28S subunit
(mtSSU) plays a role in catalysing the peptidyl-transferase
reaction, while the large 39S subunit (mtLSU) is involved in
mt-mRNA binding and decoding. These two subunits are
composed of 12S mt-rRNA (mtSSU) and 16S mt-rRNA
(mtLSU) and ribosomal proteins. The biogenesis of the mito-
chondrial ribosome is a complex process entailing a number
of auxiliary factors (Rorbach et al 2012; Dalla Rosa et al
2014). Maturation of mt-rRNA through a number of post-
transcriptional nucleotide modifications is necessary for cor-
rect folding, stability and ribosome assembly (Decatur and
Fournier 2002). However, while cytosolic rRNAs have over
200 modifications and bacterial rRNAs over 30, only nine
modified nucleotides have been identified in mt-rRNAs
(Piekna-Przybylska et al 2008).
Maturation of 12S mt-rRNA
Mt-tRNA cleavage from the mitochondrial H-strand precursor
liberates full-length 12S and 16Smt-rRNAs without a require-
ment of any further nucleolytic processing events. Five nucle-
otide modifications have been identified in the mammalian
12S mt-rRNA, with one methylated uracil (12S: m5U429,
mtDNA position: 1076), two cytosine methylations (12S:
m4C839 and m5C841, mtDNA positions: 1486 and 1488, re-
spectively) and two dimethylated adenosines (12S: m62A936
and m62A937, mtDNA positions: 1583 and 1584) (Baer and
Dubin 1981). Only two of the proteins responsible for these
post-transcriptional nucleotide modifications have been
characterised to date (Fig. 4).
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TFB1M is responsible for dimethylation of two high-
ly conserved adjacent adenines in a stem-loop structure
near the 3′ end of the 12S mt-rRNA, m62A936 and
m62A937 (Seidel-Rogol et al 2003; Metodiev et al
2009). In bacteria, this region contains the mRNA
decoding centre and the binding site for the large sub-
unit (Xu et al 2008b). The lack of TFB1M causes a
dramatic decline of 12S mt-rRNA levels, leading to a
deficiency of assembled mtSSU and results in a severe
impairment of mitochondrial translation (Metodiev et al
2009).
Another protein that plays a role in 12S mt-rRNA matura-
tion is NSUN4 (NOP2/Sun domain containing family, mem-
ber 4), which has been suggested to have a dual function. In a
complex with MTERF4, it plays a role in ribosome assembly
regulation (Camara et al 2011; Spahr et al 2012;
Yakubovskaya et al 2012). However, the NSUN4 protein on
its own is capable of m5C841 methylation of the 12S mt-
rRNA. It has been speculated that m5C841 is involved in
stabilisation of mt-rRNA folding, in cooperation with
m4C839 methylation. The methyltransferases required for
methylation of 12S mt-rRNA positions C481 and U429 re-
main unidentified (Fig. 4).
Maturation of 16S mt-rRNA
Four nucleotides are modified in the mammalian 16S mt-
rRNA: two ribose methylations of guanosine (16S: Gm1145
and Gm1370, mtDNA positions: 2815 and 3040), one ribose
methylation of uridine (16SUm1369, mtDNA position 3039),
and one pseudouridylated base (16S: Psi1397, mtDNA posi-
tion: 3067) (Dubin and Taylor 1978; Ofengand and Bakin
1997). Mitochondrial rRNA methyltransferase 1, MRM1, is
responsible for 2′-O-ribose methylation of 16S mt-rRNA po-
sition Gm1145 and is present in mitochondrial RNA granules
(Lee et al 2013; Lee and Bogenhagen 2014; Rorbach et al
2014b). In yeast mitochondria, this methylation is crucial for
the stability of the large ribosomal subunit and for ribosomal
function (Sirum-Connolly andMason 1993), however the role
of this modification in human 16S mt-rRNA has not been
investigated. Two other methylated nucleotides of the 16S
mt-rRNA, Um1369 and Gm1370 are localised in the A-loop,
an essential component of the peptidyl transferase centre of
the large subunit rRNA and are involved in the interaction
with the aminoacyl site of the mt-tRNA (Decatur and
Fournier 2002). These sites are modified by MRM2 and
MRM3 (also known as RNMTL1), respectively (Lee et al
2013; Lee and Bogenhagen 2014; Rorbach et al 2014a).
Both enzymes are localised in mitochondrial RNA granules
and are indispensable for correct mitochondrial translation and
OXPHOS function. Ineffective translation in MRM2 and
MRM3-depleted cells stems from aberrant assembly of
mtLSU (Rorbach et al 2014b). It remains to be established,
however, whether the presence of MRM2/MRM3 or
rather the presence of the actual modification of 16S
mt-rRNA is crucial for mitochondrial ribosome biogen-
esis. The enzyme responsible for pseudouridylation of
the 16S mt-rRNA is still unknown (Fig. 4).
mt-tRNA maturation
The release of mt-tRNAs from a polycistronic primary
transcript does not mark the end of their maturation
process (Fig. 2). Instead, numerous post-transcriptional
modifications are utilised to form the cloverleaf struc-
ture resulting in a stable and correctly functioning tRNA
(Helm et al 1999). A great range of chemical diversity
exists in the modifications found to mt-tRNAs, with
bases undergoing methylat ions, isomerisat ions,
thiolations, formylations, and ribosylations, along with
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others, by a multitude of nuclear factors. The impact of
a tRNA modification can be broadly divided into those
that confer structural stability and correct folding, and
those that assist proper tRNA function via altering
tRNA interaction with other factors.
Whilst many unmodified tRNAs fold into structures that
are in approximately the correct conformation (Sampson and
Uhlenbeck 1988; Harrington et al 1993), unmodified mito-
chondrial tRNAs transcribed in vitro have been demonstrated
to fold into a range of non-functional secondary structures
(Helm et al 1998). Modifications towards the core of the
tRNA typically play a role in its structure and stability, often
through the modulation of the rigidity of particular domains.
For example, saturation of the pyrimidine ring of uracil to
form dihydrouridine results in a greater range of conforma-
tional flexibility (Dalluge 1996), while the introduction of
pseudouridine, through the isomerisation of uridine, acts to
increase the structural rigidity of the tRNA (Davis 1995).
Base methylation can also influence tRNA structure in a num-
ber of ways. For example, the methylation of adenine in po-
sition 9 (A9) in human mt-tRNALys by the RNase P
subcomplex of MRPP1 and MRPP2 (HSD17B10) (Vilardo
et al 2012) impacts on tRNA structure. Unmodified mt-
tRNALys folds into a non-functional extended hairpin struc-
ture, which is not recognised by its cognate lysyl-tRNA syn-
thetase (Helm et al 1998; Sissler et al 2004). The introduction
of m1A9 alone into mt-tRNALys is sufficient to favour the
formation of the canonical cloverleaf structure by disrupting
the A9-U64 Watson-Crick base pair in the extended hairpin
(Helm et al 1999). However, the stabilising effects of the N1-
methylation of adenine have also been identified, on the T-
loop at position 58, catalysed in human mitochondria by
tRNA methyltransferase TRMT61B (Chujo and Suzuki
2012).
Modifications at tRNA residue positions 34 and 37 are
important for maintaining translation accuracy and fidelity,
representing the greatest chemical diversity found in a
tRNA’s modification profile. One or both of these posi-
tions are modified in almost all tRNAs so far studied. The
translation of an mRNA into its corresponding polypeptide
chain is dependent on the precise interactions between the
three bases (referred to as 1, 2 and 3) of the mRNA’s
triplet codon and the triplet anticodon of the cognate
tRNA (at positions 36, 35 and 34). However, owing to
degeneracy of the genetic code, multiple codons must be
recognised by a single tRNA. Degenerate codons contain
identical residues in positions 1 and 2 and are expanded
through variability in position 3. To accomplish this, the
interactions between residues 3 and 34 are non-standard,
allowing for a much greater range of possible base pairs, a
characteristic referred to as ‘wobble’. Position 34, or the
wobble base, is often occupied by a uridine, capable of
base pairing with any of the four bases due to enhanced
conformational flexibility within the anticodon loop. This
scenario is sufficient for the majority of codons in which
the residue in position 3 is entirely degenerate. However,
in a number of cases, the presence of a purine or a py-
rimidine in position 3 produces codons for different amino
acids. The increase in discrimination by the wobble base
required for accurate decoding is achieved through its
post-transcriptional modification (Johansson et al 2008).
For example, the formation of the τm5(s2)U modification
by the concerted action of GTP binding protein 3,
GTPBP3, (Villarroya et al 2008), MTO1 (mitochondrial
tRNA translation optimisation 1) (Li et al 2002) and
MTU1 (mitochondrial tRNA-specific 2-thiouridylase,
TRMU) (Yan et al 2006a), greatly favours base pairing
with purines and prevents codon misreading (Yokoyama
et al 1985) as has been demonstrated for human mt-
tRNALeu(UUR) (Kirino et al 2004). The recognition of pu-
rines at position 3 is also exemplified by the formylation
in mt-tRNAMet, the resulting f5C34 allows the tRNA to
read the AUA as well as AUG codons (Bilbille et al
2011). Whilst stringent selection of the correct cognate
tRNA is key to ensuring accuracy, a stable codon-
anticodon interaction is critical for translation efficiency.
For this reason, tRNAs with anticodons bearing U and
A in position 36 often require modification at the adjacent
position 37 (Lamichhane et al 2013a). For example, in
mammalian mitochondria position 37 contains N6-
t h r eony lca rbamoyladenos ine ( t6A37) and N6-
isopentenyladenosine (i6A37), catalysed by TRIT1 (tRNA
isopentenyltransferase 1) in human cells (Yarham et al
2014) and further modified by CDK5RAP1 (Cyclin-
dependent kinase 5 regulatory subunit associated protein
1) to form ms2i6A37 (Reiter et al 2012). A guanosine
residue may also be present at position 37 in human mt-
tRNAs, which is often methylated to form N1-
methylguanosine (m1G37) by TRMT5 (Brule et al 2004).
The m1G modification disrupts the formation of Watson-
Crick base pairing, therefore blocking potential base
pairing between G37 and the mRNA to prevent
frameshifting (Urbonavicius et al 2001; Urbonavicius
2003). By interfering with base pairing, m1G37 may also
prevent interactions with neighbouring nucleotides on the
other side of the anticodon loop to aid in the formation of
the canonical loop structure required for codon-anticodon
interactions (Cabello-Villegas et al 2002).
Lastly, post-transcriptional modifications of tRNAs may
assist in translational fidelity through ensuring correct
aminoacylation. The recognition of a tRNA by its cognate
tRNA-aminoacyl synthetase depends on the identification
of particular nucleotides and structural motifs, predomi-
nantly within the anticodon loop and the acceptor helix,
such as the discriminator base at position 73, and the 5′
terminal CCA added post-transcriptionally by TRNT1
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(Nagaike et al 2001). The majority of modifications are
assumed to contribute to tRNA identity indirectly through
the stabilisation of a recognised structural feature.
However, a direct identity element role for a modified
nucleotide, either as a recognition determinant as in Ψ35
in yeast tRNATyr (Bare and Uhlenbeck 1986), or an
antideterminant as has been described for m1G37 in yeast
tRNAAsp (Putz et al 1994), cannot be ruled out in human
mitochondrial tRNAs.
A complete set of modifications for bovine mt-
tRNAs, which share a high degree of structural and
sequence similarity with human mt-tRNAs, have recent-
ly been described (Suzuki and Suzuki 2014). From this
work, many human mt-tRNA modifying enzymes may
be predicted, bringing us closer to a comprehensive
modification profile for human mt-tRNAs (current status
summarised in Fig. 5, expanded upon in Powell et al
(2015) and Suzuki et al (2011).
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J Inherit Metab Dis (2015) 38:655–680 663
Human diseases associated with defects
of mitochondrial RNA maturation
Defects of mt-pre-RNA processing
HSD17B10
As discussed in Nucleolytic processing of mitochondrial pre-
cursor RNA, the mitochondrial RNase P complex consists of
three protein components, MRPP1, 2 and 3. The exact role of
MRPP2, also known as 17β-hydroxysteroid dehydrogenase
type 10 (HSD17B10), in the RNase P complex is unknown.
However, it is a multifunctional mitochondrial protein which,
in addition to its functions in mtRNA maturation, catalyzes
the 2-methyl-3-hydroxylbutyryl-CoA dehydrogenation
(MHBD) reaction in isoleucine metabolism, converting 2-
methyl-3-hydroxybutyryl-CoA to 2-methyl-acetoacetyl-
CoA, as well as playing a potential role in the pathogenesis
of Alzheimer’s disease (Chen and Yan 2007) (Table 1).
Patients in at least 19 independent families have been re-
ported to carry pathogenic, X-linked mutations in HSD17B10
[MIM: 300256] (HSD17B10 is located at Xp11.2) (Zschocke
2012). Affected patients suffer from a progressive loss of cog-
nitive and motor function, epilepsy, retinal degeneration and
progressive cardiomyopathy, with lactic acidosis also a com-
mon presentation. Infantile onset is most common, with onset
of symptoms following the first 6–18 months of life, resulting
in death at age 2–4 years or later. A more severe neonatal form
has been characterised with severe progressive cardiomyopa-
thy with limited neurological presentation, resulting in early
death (Perez-Cerda et al 2005). Due to the X-linked nature of
inheritance, symptoms have been shown to vary betweenmale
and female patients carrying the same mutation in HSD17B10
(Perez-Cerda et al 2005).
The severity of clinical symptoms presenting in patients
with mutations in HSD17B10 are suspected to be independent
of relative residual MHBD activity in different mutant variant
proteins (Rauschenberger et al 2010), and attempts at placing
patients on isoleucine restricted diets have had mixed success
at preventing further clinical deterioration (Zschocke et al
2000; Perez-Cerda et al 2005). Additionally, the neurodegen-
erative disorder experienced in patients with HSD17B10 de-
ficiency is dissimilar to other disorders of isoleucine metabo-
lism or other organic acidurias, and more closely resembles a
primary mitochondrial disorder (Rauschenberger et al 2010).
This evidence may suggest that the deficiency in MHBD ac-
tivity of HSD17B10 may not be the primary cause of clinical
presentation of the disease, and is instead linked to an inde-
pendent mitochondrial dysfunction.
In a recent article, Deutschmann et al (2014) have sug-
gested that the disorder associated with mutations in
HSD17B10 may instead be linked to the role of HSD17B10
(MRPP2) in mtRNA endonucleolytic processing. In this
study, patient fibroblasts harbouring a p.R130C mutation in
HSD17B10, which causes infantile onset disease, were shown
to have a lower residual protein level of HSD17B10 compared
to controls, whichwas accompanied by a reduction inMRRP1
protein, but not MRPP3. The study showed there was im-
paired processing of the H-strand precursor mtRNA transcript,
but not the L-strand, compared to controls. This deficiency in
mtRNA processing may contribute to the mitochondrial dis-
order experienced in HSD17B10 patients.
Due to the multifunctional nature of the protein, it is pos-
sible that mutants at different sites within HSD17B10 may
have independent effects on mtRNA processing and MHBD
activity, which in turn may influence the clinical presentation
and severity of the disorder.
ELAC2
Pathogenic mutations in the ELAC2 gene, which encodes the
nuclease that cleaves 3′ off mt-tRNAs, have recently been
identified [MIM: 605367] (Haack et al 2013). Initial exome
sequencing of two unrelated probands who each exhibited a
suspected infantile-onset mitochondrial disorder identified
mutations in ELAC2 as the possible underlying defect.
Further targeted sequencing of ELAC2 in 350 individuals with
oxidative phosphorylation disorders identified two additional
cases of genetic variation in ELAC2 in siblings of an unrelated
family. In this study, a total of five individuals were identified
across three independent families, harbouring either com-
pound heterozygous or homozygous mutations in ELAC2.
Likemanymitochondrial disorders, severity of disease pro-
gression varied among individuals, but all patients presented
with some consistent clinical features. All individuals present-
ed with poor growth, onset of infantile hypertrophic cardio-
myopathy prior to 6 months and elevated lactate levels and
associated (or consequent) alanine and occasional increase of
glutamine and ammonia, consistent with a status of metabolic
acidosis. Isolated complex I deficiency in skeletal muscle was
observed in all patients, with one individual also exhibiting a
complex IV deficiency. In four out of five individuals studied,
a mild to marked developmental delay was also apparent. Two
patients died before 12 months of age and a third died at the
age of 4 years.
If variants in ELAC2 were indeed the underlying primary
defect, it was expected that processing at sites 3′ to mt-tRNAs
would be hindered due to lack of ELAC2 activity. All tRNA-
mRNA junctions expected to be cleaved by the ELAC2 pro-
tein showed accumulation in patient skeletal muscle, and, to a
lesser extent, in patient fibroblasts, as assessed by qPCR. This
was confirmed by RNA-Seq and northern blotting, consistent
with the characterised RNase Z activity of ELAC2 in mito-
chondria. Notably, changes to steady state levels of correctly
processed mt-tRNAs, mt-rRNAs and mt-mRNAs were not
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Table 1 Mitochondrial transcript metabolism in human disease
Gene* MIM Function Target* Disease References
Precursor transcript processing
MRPP2
(HSD17B10)
300256 Endonucleolytic processing
(5′ end of mt-tRNA)
Precursor mt-RNA Neurological abnormalities and
cardiomyopathy
Deutschmann et al 2014
ELAC2 605367 Endonucleolytic processing
(3′ end of mt-tRNA)
Precursor mt-RNA Infantile hypertrophic
cardiomyopathy and complex I deficiency
Haack et al 2013
Transcript polyadenylation, stability & turnover
LRPPRC 607544 Post-transcriptional regulation? mt-mRNA Leigh syndrome French Canadian
type (LSFC)
Morin et al 1993; Mootha et al 2003
PNPT1 610316 RNA degradation (or RNA import) ? Encephalomyopathy, deafness Vedrenne et al 2012; von Ameln et al 2012
MTPAP 613669 mt-mRNA polyadenylation mt-mRNA Spastic ataxia Crosby et al 2010; Wilson et al 2014
mt-tRNA modification
TRNT1 612907 Addition of 3′ CCA Sideroblastic anemia with immunodeficiency,
fevers and developmental delay (SIFD)
Chakraborty et al 2014
PUS1 608109 Ψ27, Ψ28 mt-tRNA: Asp, Ile, Lys, Met,
Leu(CUN), Leu(UUR), Cys, His, Glu,
Asn, Tyr
Mitochondrial myopathy lactic acidosis
and sideroblastic anaemia
Patton et al 2005; Zeharia et al 2005;
Fernandez-Vizarra et al 2007
GTPBP3 608536 τm5U34 mt-tRNA: Lys, Leu(UUR), Trp, Gln, Glu Hypertrophic cardiomyopathy, lactic acidosis
and encephalopathy
Kopajtich et al 2014
MTO1 614667 τm5U34 mt-tRNA: Lys, Leu(UUR), Trp, Gln, Glu Hypertrophic cardiomyopathy and lactic
acidosis
Ghezzi et al 2012; Baruffini et al 2013
MTU1 (TRMU) 610230 τm5s2U34 mt-tRNA: Lys, Gln, Glu Acute infantile liver failure/mitochondrial-
associated deafness
Zeharia et al 2009; Schara et al 2011;
Uusimaa et al 2011; Gaignard et al 2013
TRIT1 – i6A37 mt-tRNA:Ser(UCN), Cys, Phe, Trp, Tyr Encephalopathy and myoclonic epilepsy Yarham et al 2014
MTFMT** 611766 Formylmethionine mt-tRNA: Met Leigh Syndrome Tucker et al 2011; Neeve et al 2013;
Haack et al 2014
List of nuclear-encoded disease-causing genes involved in precursor transcript processing, mt-mRNA transcript polyadenylation, stability and turnover and mt-tRNA modification. Mt-tRNA species with
confirmed nucleotide modification in human are underlined. The other modifications are predicted based on the analysis of bovine mt-tRNAs (Suzuki and Suzuki 2014)
** MTFMT is strictly speaking a modifier of a charged amino acid, rather than of the mt-tRNA itself
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observed, despite the accumulation of unprocessed
intermediates.
A further individual, suffering from a mitochondrial disor-
der, was characterised as having a presumed pathogenic mu-
tation in ELAC2. This patient was identified recently via ex-
ome sequencing of 53 patients carrying multiple respiratory
chain complex defects (Taylor et al 2014). In the same high-
throughput-exome sequencing study a single individual was
identified as carrying possible pathogenic mutations in the
PTCD1 gene, the protein product of which is thought to di-
rectly interact with ELAC2. However, as only a single indi-
vidual has so far been identified, and mutations in PTCD1
have not previously been associated with a mitochondrial dis-
order, further investigation will be required to confirm PTCD1
as the causative gene in this case.
Defects of mt-mRNA maturation
PNPase
Three studies have identified pathogenic mutations in the
PNPT1 gene, encoding PNPase, thought to be involved in
mtRNA turnover and possibly RNA import into mitochon-
dria, as earlier described.
The first study, by Vedrenne et al (2012), identified two
siblings, born to first-cousin healthy Moroccan parents, suf-
fering with severe but non-progressive encephalopathy ac-
companied with elevated plasma and cerebrospinal-fluid lac-
tate levels [MIM: 614932]. Affected individuals developed
severe hypotonia and movement abnormalities in late infancy.
Exome sequencing of the siblings identified a homozygous
c.1160A>G variant in the PNPT1 gene in both individuals.
This variant produces a p.Gln387Arg transition in the PNPase
protein product, with the affected glutamine residue lying
within a highly conserved domain of the protein.
Mitochondrial translation was shown to be moderately re-
duced in patient fibroblasts, which is rescued upon reintroduc-
tion of wild-type PNPase cDNA, supporting the argument that
the variant in PNPT1 is the underlying primary cause of the
mitochondrial disorder.
The second study also concerned a single consanguineous
Moroccan family, where three siblings were affected by a
severe, early onset hearing impairment in early childhood
[MIM: 614934] (von Ameln et al 2012). Here, it was shown
via genome-wide homozygosity mapping that the three affect-
ed siblings carried a homozygous c.1424A>G mutant variant
(p.Glu475Gly) in PNPT1 which co-segregated on the pedi-
gree with the hearing loss.
Recently, an individual in a third suspected family was
shown to carry compound heterozygous sequence variants in
the PNPT1 gene (Slavotinek et al 2014), a maternally
inherited mutation affecting the acceptor splice-site for exon
5, c.401-1G>A, and a paternally inherited c.1519G>T
missense mutation (p.Ala507Ser). In this case, as well as clin-
ical presentations, which are consistent with the previous re-
ports (microcephaly, myoclonic epilepsy and sensorineural
deafness), the proband also suffers from eye manifestations
in the form of left-sided peripheral chorioretinal defect and
optic atrophy (Slavotinek et al 2014).
The difference in severity and tissue specificity in the indi-
viduals affected across the three studies may reflect a different
level of residual PNPase activity for the different mutant var-
iant proteins. This example highlights the heterogeneity of the
presentation of mitochondrial disorders.
In the first two reported cases it was shown that the muta-
tions affected homo-trimerisation of PNPase. To determine
the exact mechanism perturbed in the disease, both studies
focused on the deleterious effect of the mutant PNPase vari-
ants on the reported role of PNPase in RNA import, where it
was shown that both mutant variants resulted in impaired im-
port of RNAs into mitochondria. However, the exact role of
PNPase in human mitochondria is still a subject of debate, and
it had not been addressed whether either of the mutant proteins
had any effect on the role of PNPase in the mitochondrial
matrix, where it has been shown to be involved in mtRNA
turnover (Borowski et al 2013).
mtPAP
Six individuals from a large consanguineous Old Order Amish
family were reported to carry a homozygous pathogenic mu-
tation in MTPAP. Patients suffer from a slowly progressive
autosomal-recessive neurodegenerative disorder characterised
by spastic paraparesis, cerebellar ataxia and optic atrophy
[MIM: 613669] (Crosby et al 2010). This is also often accom-
panied with learning difficulties.
Genome wide linkage and homozygosity mapping of af-
fected individuals identified a region of 6.5 Mb at chromo-
some 10p11.23 as likely to contain the disease locus. Targeted
sequencing of genes within this region identified a homozy-
gous c.1432A>G mutation in MTPAP which cosegregated
with the disease phenotype. The mutation results in a predict-
ed p.N478D substitution in a highly conserved region of
mtPAP protein.
Mitochondrial poly(A) tail assays using RNA from blood
of affected patients revealed a profound reduction of
polyadenylation of several mtRNAs in homozygous carriers
(Crosby et al 2010), although transcripts did remain
oligoadenylated (<10 nt 3′ extension), and a further study
was able to confirm that the p.N478D mutant mtPAP retained
residual oligoadenylation activity, but not polyadenylation ac-
tivity (Wilson et al 2014). This highlights polyadenylation of
mitochondrial mRNAs as essential for mitochondrial gene
expression, as reduction of polyadenylation due to impaired
mtPAP activity was later shown to cause a mitochondrial
translation defect (Wilson et al 2014).
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LRPPRC
Leigh syndrome French Canadian (LSFC) type [MIM:
220111] is a severe autosomal recessive disorder which pre-
sents in the geographically isolated Saguenay-Lac-Saint-Jean
region of Quebec, resulting from mutations in the LRPPRC
gene. In this region, it is estimated that ~1 in 23 adults are
carriers of the affected mutant LRPPRC allele, resulting in
LSFC presenting in around 1 in 2000 births (Morin et al
1993). Genealogical analysis suggests the LRPPRC founder
mutation to originate from individuals of the French-Canadian
population in Europe in the 17th Century. This founder allele
carries a p.A354V mutation at a highly conserved residue of
the LRPPRC protein.
LSFC is characterised by severe COX deficiency, which
particularly affects the liver and brain, and to a lesser extent in
fibroblasts and skeletal muscle, due to a failure to assemble the
holoenzyme complex (Merante et al 1993). As with classical
Leigh syndrome, affected LSFC patients suffered from a se-
vere neurological disorder characterised by subacute
necrotising encephalopathy, but also presented with
microvesicular steatosis (Morin et al 1993), likely due to the
low levels of COX activity in the liver of patients (Merante
et al 1993). Other common presentations include a moderate
developmental delay, hypotonia, ataxia, strabismus,
opthalmoplegia, optic atrophy and mild facial dysmorphia.
Patients suffer from elevated lactate levels in blood and cere-
brospinal fluid, and most affected individuals died of fulmi-
nant metabolic acidosis, at an average age of between 3 and
5 years (Morin et al 1993).
At a stage when whole exome sequencing was not yet
available, the affected genomic locus was narrowed down
using genome-wide linkage disequilibrium mapping to a
~2 cM region at 2p16-21 (Lee et al 2001). An integrative
genomics approach, where the combination of available ge-
nomic DNA data, identification of mRNAs which co-express
with known mitochondrial genes and proteomic analysis of
mitochondrial proteins, was further used to identify LRPPRC
as the affected mitochondrial gene in LSFC (Mootha et al
2003). In this study, 21 out of 22 patients carried homozygous
founder mutation alleles, with the remaining patient a com-
pound heterozygote.
In patients fibroblasts, a reduction in level of the mutant
LRPPRC protein in mitochondria was associated with a spe-
cific reduction in steady state levels of COI and COIII
mRNAs, and an accompanied specific reduction in COI and
COIII translation products (Xu et al 2004), which could ex-
plain the specific COX deficiency in LSFC patients (Merante
et al 1993). This would suggest that LRPPRC has a specific
mRNA stabilising function for COI and COIII mRNAs.
Recently, it has been proposed that tissue specific differ-
ences in the levels of LRPPRC and its interacting partner
SLIRP in affected tissues may account for the tissue specific
biochemical deficiencies encountered in LSFC. While there is
an almost complete lack of complex IV in the liver, there is
only a 50 % reduction of COX assembly in the heart
(Sasarman et al 2015a).
In unaffected control tissues, fibroblasts exhibited the
highest levels of the LRPPRC-SLIRP protein complex, with
lower levels in muscle and liver, and almost undetectable
levels in control heart tissue (Sasarman et al 2015b). This
contrasts with levels of assembled complex IV in these control
tissues, where heart carries the highest level of complex IV,
and liver and fibroblasts have a reduced level. This may sug-
gest a tissue-specific post-transcriptional handling of mito-
chondrial mRNAs, where heart tissue may be less dependent
on activity of the LRPPRC-SLIRP complex compared to heart
and brain, which are the main affected tissues when LRPPRC
activity is reduced in LFSC.
Additionally, further depletion of LRPPRC protein levels
in patient myoblasts and differentiated myotubes, which suffer
from complex I as well as complex IV deficiency, leads to a
general OXPHOS complex deficiency in all complexes with
subunit contributions from mtDNA (Sasarman et al 2015a). It
is possible therefore that while the p.A354V founder mutation
protein specifically affects COX transcripts and therefore has
a greatest effect on cytochrome oxidase assembly, alternative
mutations which confer further loss of residual LRPPRC ac-
tivity may lead to a more generalised combined OXPHOS
deficiency.
Defects of mt-rRNA maturation
Most enzymes that play a role in mt-rRNA maturation have
been discovered only recently and very little is known about
their possible pathological role. Mouse models exist for only
two of these genes (TFB1M and NSUN4) and for both of
them, homozygous gene ablation is embryonic lethal. It has
been suggested that the function of TFB1M as 12S mt-rRNA
methylase might be related to aminoglycoside antibiotics in-
duced deafness (Raimundo et al 2012). However, recent meth-
ylation analysis in patients harbouring mtDNA mutation that
predisposes to hearing loss following aminoglycoside antibi-
otic exposure show no difference in 12S mt-rRNA methyla-
tion level compared to controls (O'Sullivan et al 2015).
Defects of mitochondrial tRNA maturation
TRNT1
The universally conserved CCA sequence is found on the 3′
terminus of all tRNAs. However, it is uncoded in almost all
species, with a post-transcriptional polymerisation event re-
quired to produce the full length tRNA. Once mature, the
newly polymerised 3′ terminus acts as the amino acid attach-
ment site for the tRNAs cognate aminoacyl-tRNA synthetase.
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In human mitochondria, this sequence is created by tRNA-
nucleotidyltransferase 1 (TRNT1) (Fig. 5) (MIM: 612907).
A cohort of patients presenting with SIFD (Sideroblastic anae-
mia associated with immunodeficiency, periodic fevers and
developmental delay) were identified as carrying mutations
in TRNT1 (Chakraborty et al 2014). Sideroblastic anaemia,
a condition characterised by a reduced ability to incorporate
iron into haemoglobin, has been linked to deficiencies in haem
synthesis, mitochondrial iron-sulphur cluster biogenesis and
mitochondrial translation (Fleming 2011). Some patients were
also found to have sensorineural hearing loss, cardiomyopathy
and central nervous system abnormalities. All but one of the
mutations described were found to have diminished polymer-
isation activity in an in vitro assay, with the degree of the
enzymatic impairment found to correlate with the range of
clinical severity found. More recently, two further individuals
carrying distinct TRNT1 mutations have been characterised
and shown to exhibit an impairment of CCA addition specific
to mt-tRNASer(AGY) (Sasarman et al 2015b). Despite this, the
two individuals presented with varied clinical features: acute
lactic acidosis, severe developmental delay, hypotonia, micro-
cephaly, seizures, progressive cortical atrophy, neurosensorial
deafness, sideroblastic anaemia and renal Fanconi syndrome
in one case, gait ataxia, dysarthria, gross motor regression,
hypotonia, ptosis and ophthalmoplegia in the other.
PUS1
Given the stabilising role of pseudouridine (Ψ), its absence in
mt-tRNAs would be expected to negatively impact translation
through the disruption of structure dependent processes, such
as its recognition by a cognate aminoacyl-tRNA synthetase, or
its accommodation into the P or A site of the ribosome. Of the
13 pseudouridine synthases identified in humans, PUS1 is by
far the most well characterised, with loss of functionmutations
in PUS1 resulting in diminished levels of Ψ27 and Ψ28 in
human mitochondrial tRNAs (MIM: 609109) (Patton et al
2005) (Fig. 5). Patients with mitochondrial myopathy, lactic
acidosis and sideroblastic anaemia (MLASA), along with a
concordant decrease in mitochondrial translation rate, have
been identified as carrying causative mutations in PUS1
(Bykhovskaya et al 2004a; Fernandez-Vizarra et al 2007).
Despite its dual localisation, with substrates including both
cytosolic and mitochondrial tRNAs, patients with deleterious
mutations in PUS1 have a characteristic mitochondrial pheno-
type. The relative sparseness of modifications in mitochondri-
al tRNAs may result in a greater susceptibility compared to
their cytosolic counterparts. For example, a stabilising Ψ55
modification that is present in cytosolic tRNAs is frequently
absent in mitochondrial tRNAs. Interestingly, Pus1p, the yeast
homolog of PUS1 is found to be non-essential for viability,
but is lethal in combination with mutations in Pus4p, the
tRNA Ψ55 synthase (Grosshans et al 2001).
GTPBP3/MTO1
The incorporation of taurinomethyl at position 34 to form 5-
taurinomethyluridine (τm5U) has been identified in five mam-
malian mt-tRNAs: mt-tRNALeu(UUR), mt-tRNATrp, mt-
tRNALys, mt-tRNAGln and mt-tRNAGlu (Suzuki and Suzuki
2014). The enzymatic activity responsible for the formation of
5-taurinomethyluridine (τm5U) has yet to be definitively dem-
onstrated in humans, however GTPBP3 (MIM: 608536) and
MTO1 (MIM: 614667), acting in unison, represent the most
likely candidates. Both GTPBP3 and MTO1 have been local-
ised to the mitochondria, and are capable of complementing
the mitochondrial phenotypes in yeast strains carrying dele-
tions in their corresponding homologs, MSS1 and MTO1 (Li
and Guan 2002; Li et al 2002). Patients presenting with hy-
pertrophic cardiomyopathy, lactic acidosis and a combined
OXPHOS deficiency have been found to carry mutations in
GTPBP3 (Kopajtich et al 2014) and MTO1 (Ghezzi et al
2012; Baruffini et al 2013). The high degree of similarity of
clinical phenotypes between patients with GTPBP3 and
MTO1 mutations, an uncharacteristic attribute of mitochon-
drial disease causing genes, corroborates the notion that these
two enzymes act in tandem. The phenotype of an MTO1-
deficient mouse model is found to accurately reflect that of
the above patients (Becker et al 2014), the severity of which is
found to be ameliorated by a ketogenic diet (Tischner et al
2015). Additionally, both GTPBP3 and MTO1 have been
identified through linkage analysis as modifier genes in non-
syndromic deafness caused by am.1555A>Gmutation in 12S
mt-rRNA (Bykhovskaya et al 2004b). Despite being present
as a homoplasmic population, the m.1555A>G mutation re-
sults in a broad range of clinical severity from individual to
individual, with this variance being modulated by the co-
inher i t ance of nuc lea r-encoded modi f i e r genes
(Bykhovskaya et al 1998). Corroboratively, yeast strains bear-
ing a 15S rRNA mutation in the corresponding mtDNA posi-
tion to human m.1555A>G are found to result in a respiratory
defect only in conjunction with mutations in MSS1 and
MTO1, yeast orthologous of human GTPBP3 and MTO1,
respectively (Decoster et al 1993; Colby et al 1998).
MTU1 (TRMU)
Three of the five mt-tRNAs identified as putative GTPBP3/
MTO1 substrates carry a more extensively modified 5-
taurinomethyl-2-thiouridine (τm5s2U) wobble base in their
mature forms: mt-tRNALys, mt-tRNAGln and mt-tRNAGlu
(Suzuki et al 2002). As for GTPBP3 and MTO1, yeast dele-
tion strains have greatly assisted in identifying the responsible
enzymatic activity, with the loss of the thiouridylase MTU1
(MTO2) resulting in diminished 2-thiolation of mitochondrial
tRNAs, with a corresponding impairment of mitochondrial
translation. Depletion of the human homolog, MTU1 (MIM:
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610230), also known as TRMU, a mitochondrially localised
protein capable of complementing yeast MTU1, also produces
a dramatic reduction in tRNA thiolation (Umeda et al 2005).
Numerous patients with reversible infantile respiratory chain
deficiency, a condition characterised by acute liver failure in
infancy, have now been identified as carrying causative muta-
tions in MTU1 (Zeharia et al 2009; Schara et al 2011; Uusimaa
et al 2011; Gaignard et al 2013). The hypomodification of
substrate tRNAs was not found to result in a significant loss
of stability, therefore the resulting defective mitochondrial
translation is believed to be due to their impaired decoding
capabilities (Zeharia et al 2009). Patients present during early
infancy with symptoms of liver dysfunction, however, if they
survive the first few months of life, make a full spontaneous
recovery. It is postulated that infants may experience a window
of vulnerability during neonatal development due to a limited
availability of sulphur. MTU1 is predicted to be dependent on
the activity of a cysteine desulfurase, NFS1, to transfer sulphur
from cysteine (Nakai et al 2004), an amino acid that is de-
scribed as conditionally essential, at least in early life (Zlotkin
and Anderson 1982; Zlotkin and Cherian 1988). Cysteine sup-
plementation during this period has therefore been proposed as
a potential treatment (Boczonadi et al 2013). As with GTPBP3
and MTO1 above, MTU1 has also been implicated as a mod-
ifier gene in mitochondrial deafness (Yan et al 2006b).
TRIT1
The existence of the i6A37 modification has been demonstrat-
ed to improve translation efficiency through the stabilisation
of cognate codons, with its loss in yeast, due to deletion of the
tit1 gene, resulting in mitochondrial dysfunction and slow
growth (Lamichhane et al 2013b). The homologous
isopentyltransferase in humans, TRIT1, was initially identi-
fied as a tumour suppressor gene (Spinola et al 2005) with
certain variants being associated with lung cancer progression.
Subsequent siRNA-mediated TRIT1 depletion studies dem-
onstrated diminished i6A37 in cytosolic and mitochondrial
tRNAs (Lamichhane et al 2013a). Siblings with encephalop-
athy and myoclonic epilepsy have been identified as carrying
causative mutations in TRIT1 with a corresponding loss of the
i6A modification and compromised mitochondrial translation
(Yarham et al 2014).
MTFMT
As in all translation systems, polypeptide synthesis in mito-
chondria is initiated with a methionine residue. However,
metazoan mitochondria differ in that only a single methionine
tRNA is utilised for both initiation and elongation.
Segregation instead occurs via a post-transcriptional modifi-
cation, with the initiator mt-tRNAMet undergoing an unusual
formylation on the methionine residue charged to its 3′ end,
thereby increasing its affinity for the mitochondrial initiation
factor (IF2mt) (Spencer and Spremulli 2004). Deficiencies in
mt-tRNAMet-formylation due to mutations in mitochondrial
methionyl-tRNA formyltransferase (MTFMT, MIM:
611766) have been identified in a number of patients with
Leigh syndrome and combined OXPHOS deficiency (Neeve
et al 2013; Haack et al 2014). Significantly reduced mitochon-
drial translation rates have been identified as the result of
pathogenic MTFMT mutations (Tucker et al 2011) and a se-
verely diminished activity of these variants has been demon-
strated in vitro (Sinha et al 2014).
Mt-tRNA aminoacyl synthetases
The key role of mitochondrial aminoacyl-tRNA synthetases
(mtARSs) in human pathology affecting mitochondrial trans-
lation has been well recognised. However, this large group of
disease genes is not covered by this review. Existing recent
papers extensively describe the mitochondrial pathologies
caused by genetic defects in ARSs (Konovalova and
Tyynismaa 2013; Diodato et al 2014; Vanlander et al 2014).
Maturation defects related to primary mtDNA mutations
Primary mutations in mtDNA can affect almost any step of
mtRNA maturation. Below we provide an overview of path-
ological mtDNA mutations for which involvement in mt-
tRNA, mt-rRNA and mt-mRNA maturation by nuclear
encoded genes has been documented.
There are two main types of mtDNA alterations: point
mutations, which involve a change of one or a few nucle-
otides, and large-scale rearrangements, such as large dele-
tions. Unlike the nuclear genome, there are multiple mito-
chondrial genomes per cell. Therefore, unlike nuclear mu-
tations, which can be either heterozygous or homozygous,
mtDNA mutations may be present at any fraction, a con-
dition referred to as heteroplasmy. Cellular physiology is
affected only if the mutation fraction in a given cell ex-
ceeds a certain threshold, typically >70–90 %, depending
on the type of variant and tissues affected. The percentage
of mutant mtDNA may vary among individuals and
among organs and tissues within the same patient. This,
in part, explains the varied clinical phenotype seen in
individuals with pathogenic mtDNA mutations (Sciacco
et al 1994; Chinnery et al 1997). To complicate this issue
even further, one particular base substitution can cause
different symptoms in different patients, while a particular
syndrome can usually be caused by several possible mu-
tant variants and patients can even evolve from one dis-
ease phenotype into another (Schapira 2006). It falls out-
side the scope of this review to discuss all pathogenic
variations.
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Primary mutations interfering with mt-mRNA maturation
A primary mtDNA mutation interfering with mt-mRNA mat-
uration has been described in two reports. An m.9205ΔTA
microdeletion, on the boundary of two genes, ATP6 and
COIII has been reported to underlie cases of seizures and
lactic acidosis. Encephalopathy has been observed in only
one patient (Seneca et al 1996; Jesina et al 2004). Although
the two unrelated patients have identical, nearly homoplasmic
mutation levels, biochemical consequences of this
microdeletion appear to be very different. One patient had
no altered primary transcript processing, but a rapid
deadenylation leading to enhanced mt-mRNA decay (Seneca
et al 1996; Temperley et al 2003), while the other patient
showed affected processing of the primary ATP8/6-COIII
transcripts, without polyadenylation impairment (Jesina et al
2004).
Primary mutations interfering with mt-rRNA maturation
Point mutations that interfere with mt-rRNA maturation are
actually alterations in mt-tRNALeu(UUR), not in mt-rRNA itself
(Fig. 6, bold circles). The common m.A3243A>G MELAS
(mitochondrial encephalomyopathy, lactic acidosis and
stroke-like episodes) mutation (King et al 1992), as well as
m.3271 T>C, m.3303C>T (Koga et al 2003), m.3302A>G
(Bindoff et al 1993), m.3260A>G and m.3256C>T
(Rossmanith and Karwan 1998), all interfere with end pro-
cessing of mt-tRNALeu(UUR) . This causes an accumulation
of a precursor RNA consisting of 16S mt-rRNA linked to
mt-tRNALeu(UUR) and ND1 (also known as RNA19)
(Rossmanith and Karwan 1998). Although these mutations
seem to interfere with 16S mt-rRNA maturation it is presum-
ably not the crucial disease-causing molecular pathway in
patients (see below, Table 2).
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affecting mitochondrial RNA
maturation. Schematics of the
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Table 2 Primary mutations in mtDNA that affect mt-tRNA maturation
Affected gene Mutation Location Position Molecular effect on mt-tRNA
maturation
Associated phenotypes References
mt-tRNAPhe m.T582T>C Acc-stem 6 aminoacylation MM Ling et al 2007
m.G583G>A Acc-stem 7 aminoacylation MELAS / MM & EXIT Ling et al 2007
m.A606A>G AC-stem 29 aminoacylation Myoglobinuria Ling et al 2007
m.A608A>G AC-stem 31 aminoacylation Tubulo-interstitial nephritis Ling et al 2007
m.G611G>A AC-loop 34 aminoacylation MERRF Ling et al 2007
m.T618T>C AC-stem 41 aminoacylation MM Ling et al 2007
m.G622G>A Variable region 45 aminoacylation EXIT & DEAF Ling et al 2007
mt-tRNALeu(UUR)
mt-tRNAIle
m.A3243A>G D-loop 14 aminoacylation 3′ and 5′ end processing
wobble base modification
MELAS / LS / DMDF / MIDD / SNHL /
CPEO / MM / FSGS / cardiac+multi-
organ dysfunction
Rossmanith and Karwan 1998; Yasukawa
et al 2000a; Koga et al 2003; Sohm et al 2003;
Kirino et al 2004; Levinger et al 2004;
Yasukawa et al 2005; Sasarman et al 2008
m.A3243A>T D-loop 14 aminoacylation MM / MELAS / SNHL / CPEO Sohm et al 2003
m.C3256C>T D-stem 25 5′ end processing MELAS Rossmanith and Karwan 1998
m.A3260A>G AC-stem 29 5′ end processing MELAS Rossmanith and Karwan 1998
m.T3271T>C AC-stem 40 3′ and 5′ end processing wobble base
modification
MELAS / DM Rossmanith and Karwan 1998; Kirino et al 2004
m.C3287C>A T-loop 56 3′ end processing Encephalomyopathy Levinger and Serjanov 2012
m.A3288A>G T-loop 57 3′ end processing MM Levinger and Serjanov 2012
m.T3291T>C T-loop 60 3′ end processing MELAS / MM / DEAF+cognitive impairment Levinger and Serjanov 2012
m.A3302A>G Acc-stem 71 3′ and 5′ end processing MM Bindoff et al 1993; Rossmanith and Karwan
1998;
Levinger et al 2004
m.C3303C>T Acc-stem 72 3′ and 5′ end processing CCA addition MMC Koga et al 2003; Levinger et al 2004
m.A4269A>G Acc-stem 7 3′ end processing FICP Levinger et al 2003
m.T4274T>C D-stem 12 aminoacylation 3′ end processing CPEO/motor neuron disease Kelley et al 2000; Levinger et al 2003
m.T4285T>C AC-stem 27 3′ end processing aminoacylation CPEO Kelley et al 2000; Levinger et al 2003
m.A4295A>G AC-loop 37 3′ end processing MHCM / maternally inherited hypertension Levinger et al 2003
m.G4298G>A AC-stem 40 aminoacylation CPEO/MS Kelley et al 2000
m.G4308G>A T-stem 50 3′ end processing CPEO (Schaller et al 2011
m.G4309G>A T-stem 51 3′ end processing CPEO Levinger et al 2003
m.A4317A>G T-loop 59 3′ end processing CCA-addition
aminoacylation
FICP / poss. hypertension factor Degoul et al 1998; Kelley et al 2001; Levinger
et al 2003;
Tomari et al 2003; Levinger and Serjanov
2012
m.C4320 C>T T-stem 62 3′ end processing Mitochondrial encephalocardiomyopathy Levinger et al 2003
mt-tRNAMet and
tRNAGln
m.A4401A>G junction site of tRNAMet and
tRNAGln
3′ and 5′ end processing LVH hypertension+ventricular hypertrophy Zhu et al 2009
mt-tRNAAsn m.C5703C>T AC-stem 27 aminoacylation CPEO / MM Hao and Moraes 1997
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Table 2 (continued)
Affected gene Mutation Location Position Molecular effect on mt-tRNA
maturation
Associated phenotypes References
mt-tRNATyr m.A5874A>G D-loop 22 aminoacylation EXIT Bonnefond et al 2008
m.G5877G>A D-loop 17 aminoacylation CPEO Bonnefond et al 2008
mt-tRNASer(UCN) m.A7443A>G pre-tRNA 3′ end 3′ end processing DEAF Yan et al 2006a
m.G7444G>A pre-tRNA 3′ end 3′ end processing LHON / SNHL / DEAF Yan et al 2006b
m.A7445A>C pre-tRNA 3′ end 3′ end processing DEAF Levinger et al 2001; Yan et al 2006a
m.A7445A>G pre-tRNA 3′ end 3′ end processing SNHL Yan et al 2006b
m.7472insC Variable region 46 aminoacylation 3′ and 5′ end processing MM / DMDF modulator Toompuu et al 2002; Toompuu et al 2004
m.A7480A>G AC-loop 38 post-transcriptional modification MM Yarham et al 2014
m.C7497C>T D-stem 22 post-transcriptional modification MM / EXIT Mollers et al 2005
m.A7510A>G Acc-stem 5 3′ end processing SNHL Yan et al 2006a
m.A7511A>G Acc-stem 4 3′ end processing SNHL Yan et al 2006b
m.A7512A>G Acc-stem 3 post-transcriptional modification 3′ end
processing
PEM / MERME Mollers et al 2005; Yan et al 2006a
mt-tRNALys m.G8313G>A D-stem 24 aminoacylation MNGIE / progressive mito cytopathy Sissler et al 2004
m.G8328G>A AC-stem 39 aminoacylation Mito encephalopathy / EXIT with MM
and ptosis
Sissler et al 2004
m.A8344 A>G T-stem 55 wobble base modification MERRF / LD / depressive mood disorder /
leukoencephalopathy / HCM
Yasukawa et al 2000a; Yasukawa et al 2001;
Yasukawa et al 2005
m.T8362 T>G Acc-stem 71 aminoacylation MM Sissler et al 2004
m.G8363G>A Acc-stem 72 aminoacylation MICM+DEAF / MERRF / Autism / LS / Ataxia+-
Lipomas
Sissler et al 2004; Bornstein et al 2005
mt-tRNAGly m.A10044A>G T-loop 59 CCA-addition 3′ end processing SIDS Tomari et al 2003; Levinger and Serjanov 2012
mt-tRNAHis m.G12192G>A T-loop 59 3′ end processing MICM Levinger and Serjanov 2012
m.T12201T>C Acc-stem 68 aminoacylation DEAF Gong et al 2014
mt-tRNAPro m.G15990G>A AC-loop 36 post-transcriptional modification MM Brule et al 1998
List of all known (to our knowledge) disease-causing mtDNA mutations that affect mt-tRNA processing with their possible molecular effect and associated phenotypes. Abbreviations: CPEO Chronic
progressive external ophthalmoplegia; DEAFMaternally inherited deafness; DMDiabetes mellitus;DMDFDiabetes mellitus & deafness; EXIT Exercise intolerance; FICP Fatal infantile cardiomyopathy
plus, a MELAS-associated cardiomyopathy; FSGS Focal segmental glomerulosclerosis; HCM hypertrophic cardiomyopathy; LD/LS Leigh disease/syndrome; LVH Left ventricular hypertrophy; MELAS
Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes; MERME MERRF/MELAS overlap disease; MERRF Myoclonic epilepsy and ragged red muscle fibers; MICM Maternally
inherited cardiomyopathy; MIDD Maternally inherited diabetes and deafness; MHCM Maternally inherited hypertrophic cardiomyopathy; MM Mitochondrial myopathy; MMC Maternal myopathy and
cardiomyopathy;MNGIEMitochondrial neurogastrointestinal encephalopathy disease;MSMultiple sclerosis; PEM Progressive encephalopathy; SIDS Sudden infant death syndrome; SNHL Sensorineural
hearing loss
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Primary mutations causing mt-tRNA maturation defects
While mt-tRNA genes only count for approximately 5 % of
the total mtDNA sequence, they have been linked with the
majority of mitochondrial DNA diseases (Anderson et al
1981; Yarham et al 2010). Different base substitutions in the
same mt-tRNA or even the same point mutation can lead to
different clinical features. The molecular mechanisms are of-
ten poorly understood. Some mutations disrupt transcription
factor binding, while others lead to codon recognition prob-
lems. The same base substitution can have an effect on more
than one maturation step. This has been shown for the MERR
F (myoclonic epilepsy with ragged red fibers) m.8344A>G
and MELAS m.3243A>G mutation amongst others. We will
discuss the molecular mechanism by which these two muta-
tions contribute to pathogenesis only briefly; more details can
be found in a review by Yarham et al (2010).
Primary mutations interfering with mt-tRNA end
processing Following polycistronic transcription, endonu-
cleolytic 5′- and 3′-end cleavage of precursor mt-tRNA mol-
ecules and subsequent 3′-CCA addition are essential to pro-
ducemature mt-tRNAs. Several point mutations interfere with
one or more of these steps (Table 2, Fig. 6, green, yellow and
violet).
Only a few studies have analysed the effect of mt-tRNA
mutations on 5′ end leader sequence processing. Ten muta-
tions in the mt-tRNALeu(UUR) gene were analysed. Four of
them, all associated with MELAS, showed a great decrease
in RNase P processing, especially m.3256C>T (Moraes et al
1993). This leads to a precursor RNA consisting of 16S mt-
rRNA linked to mt-tRNALeu(UUR) and ND1 as explained
above (Rossmanith and Karwan 1998). It also has been shown
that m.7472insC impairs 5 ′ end processing of mt-
tRNASer(UCN). Interestingly, this insertion also causes 3′ end
processing impairment and it was shown that misprocessing at
the 3′ end promotes misprocessing at the 5′ end.
Alterations near the mt-tRNA 3′ end could have a deleteri-
ous effect on 3′ end endonucleolytic processing. This is indeed
observed for tRNALeu(UUR) mutations m.3303C>T and
m.3302A>G as both show a strong interference with 3′ end
cleavage (Levinger et al 2004). Interestingly, also non-coding
mutations in the pre-tRNA 3′ end of mt-tRNASer(UCN) strong-
ly affect the efficiency of 3′ end processing. Four base substi-
tutions were investigated and displayed different effects.
m.7443A>G and m.7445A>C gave a strong decrease in
ELAC2 efficiency, while another mutation of the same nucle-
otide (m.7445A>G) has a lower decrease, although cleavage
predominantly shifts one nucleotide towards the 3′ end from
the normal cleavage site. m.7444G>A shows an increased
efficiency, but this cleavage has also shifted by one nucleotide
in the 3′ direction of the normal cleavage site (Yan et al
2006a).
Pathogenic substitutions in the mt-tRNA T-arm may also
cause impaired 3′ end cleavage, as the T-arm plays an impor-
tant role in ELAC2 recognition (Hopkinson and Levinger
2008). All mt-tRNAs with a pathogenic mutation in the T-
arm studied by Levinger and Serjanov (2012), showed a re-
duced ELAC2 processing efficiency. The strongest decrease
was observed in the mt-tRNAIle m.4317A>G mutation. This
effect on 3′ end cleavage is presumably due to a structural
change in the T-arm that impairs precursor binding to
ELAC2 (Levinger and Serjanov 2012). Another study
analysed the effect of pathogenic mutations in mt-tRNAIle
on 3′ end cleavage. Ten base substitutions were investigated
and they all showed a reduced ELAC2 processing, confirming
the importance of the T-arm in 3′ end cleavage. However, the
mt-tRNAIle m.4269A>G mutation, located in the acceptor
stem, caused the greatest decrease in 3′ processing efficiency.
Other substitutions in the acceptor stem such as m.7512A>G,
m.7511A>G and m.7510A>G in mt-tRNASer(UCN) also pro-
duce a mild decrease in ELAC2 processing (Yan et al 2006b).
CCA addition on the 3′ end of mt-tRNAs is another essen-
tial step for mt-tRNA maturation. Only few substitutions are
known to impair CCA addition by TRNT1, such as
m.4317A>G in mt-tRNAIle (Tomari et al 2003). However,
as mentioned above, this mutation also severely impairs 3′
end cleavage (Levinger and Serjanov 2012). It is speculated
that the effect on CCA addition is the result of inappropriate
positioning of the tRNA substrate on the enzyme, possibly
owing to the structural change in the T-arm. Another mutation
that affects CCA addition, m.3303C>T in mt-tRNALeu(UUR),
is located in the acceptor stem and presumably decreases the
affinity of the enzyme (Levinger et al 2004).
Primary mutat ions interfer ing with mt-tRNA
aminoacylation Only mature and correctly folded mt-
tRNAs can be aminoacylated. Therefore, many mt-tRNAmu-
tations impair aminoacylation efficiency or lead to
mischarging (Fig. 6, red). Mutations that frequently affect
mt-tRNA aminoacylation are located in the acceptor stem,
such as mt-tRNALys m.8362 T>G and m.8363G>A (Sissler
et al 2004). D-loop mutations that lead to reduced
aminoacylation have also been reported. For example, mt-
tRNATyr m.5874A>G and m.5877G>A (Bonnefond et al
2008) impair tyrosylation by perturbing the tertiary folding
and destabilising the D-loop. Interestingly, two different sub-
stitutions of the same nucleotide (position 14) of mt-
tRNALeu(UUR), m.3243A>G and m.3243A>T lead to mark-
edly different losses in leucylation efficiency (10-fold and
300-fold, respectively), possibly due to their function in rec-
ognition by its cognate tRNA-aminoacyl synthetase (Asahara
et al 1998; Sohm et al 2003). The m.3243A>G MELAS mu-
tation also leads to mischarging and consequently to amino
acid misincorporation during mitochondrial translation
(Sasarman et al 2008). Mischarging is also suggested to
J Inherit Metab Dis (2015) 38:655–680 673
contribute to pathogenesis of another MELAS mutation
(m.3271 T>C) (Hayashi et al 1993; Sasarman et al 2008).
As discussed above, mutations in the T-arm are generally
more prone to impair 3′ end cleavage, while mutations in the
D-loop tend to affect aminoacylation. It is speculated that
there might be a reciprocal relationship, at least for
tRNALeu(UUR). Mutations that strongly reduce 3′ end process-
ing seem to have little or no effect on aminoacylation after
cleavage, while those with reduced aminoacylation capacity
affect 3′ processing the least (Levinger et al 2003). Despite
this, it is difficult to predict the pathological mechanism based
on the position of the substituted nucleotide. For example, two
mutations at nucleotide position 72 of mt-tRNALeu(UUR)
(m.3303C>T) and mt-tRNALys (m.8363G>A) have opposite
effects (Tuppen et al 2012), with the different mutations either
causing impaired 3′ end processing and CCA addition, but
with unaffected aminoacylation (Levinger et al 2003; Sohm
et al 2003) or a diminished aminoacylation capacity
(Bornstein et al 2005), respectively.
Although many mutations have been reported to affect
aminoacylation, it is usually unknown whether this is the primary
effect of the mutation or the consequence of a structural change in
the mt-tRNA caused by the nucleotide substitution. This was
shown for mutations in the mt-tRNAPhe gene. All studied patho-
genic mutations had an effect on aminoacylation, but only in one
of them, m.611G>A, an atypical MERRF mutation (Mancuso
et al 2004), this seems to be the primary effect (Ling et al 2007).
Primary mutat ions interfering with mt-tRNA
modifications An important step in the post-transcriptional
maturation of mt-tRNA is modification of specific nucleotides
(see above, Fig. 6, blue). The following mutations have been
associated with a loss of taurinomethyl modification at the wob-
ble base (position 34): two in mt-tRNALeu(UUR), m.3243A>G
and m.3271 T>C (Yasukawa et al 2000a) and one in mt-
tRNALys, m.8344A>G (Yasukawa et al 2000b). Wild-type mt-
tRNALeu(UUR) recognises UUG and UUA, while mt-tRNALys
translates UUU and UUC. Interestingly, the two mt-
tRNALeu(UUR) mutations were shown to have a severe reduced
UUG translation, while UUA recognition was apparently unaf-
fected (Kirino et al 2004), whereas mt-tRNALys m.8344A>G
leads to a complete loss of codon-anticodon pairing for both
UUU and UUC (Yasukawa et al 2001). There are two reported
mutations at mt-tRNA position 36, m.15990G>A in mt-
tRNAPro and m.7480A>G in mt-tRNASer(UCN), both linked with
mitochondrial myopathy, that directly affect modification of the
neighbouring nucleotide (position 37) (Brule et al 1998; Yarham
et al 2014). Enzymes involved in mt-tRNA maturation, such as
MTO1, GTPBP3, MTU1 or TRIT1, must have a broad specific-
ity, so their function might be structure-dependent rather than
sequence-dependent. In a wider context, this could explain why
several mutations have an effect on multiple levels, since several
pathogenic base substitutions introduce structural changes.
Concluding note
Recent research has revealed the important role of mtRNA post-
transcriptional maturation in human mitochondrial disease, with
mutations in several nDNA- and mtDNA-encoded genes being
identified as the genetic cause for these disorders (Tables 1 and
2). Nonetheless, the mechanistic details for the genesis of pathol-
ogies associated with defects in mtRNA metabolism remain
poorly understood. It is now time to strengthen our efforts to
elucidate the molecular machinery and mechanisms responsible
for regulating post-transcriptional stages of mtRNA biology.
Special attention should be given to functionally assign novel
genes involved in mtRNAmetabolism. This point is particularly
important for a further development of mitochondrial medicine
as, despite recent advances in next-generation sequencing tech-
nologies, defining the genetic cause of the many unsolved cases
of mitochondrial disease remains a major challenge. This re-
search will help to understand the remarkable heterogeneity of
human pathologies associated with defects of mtRNA metabo-
lism (Table 1) and to stimulate further studies aimed at the de-
velopment of effective treatments for these otherwise untreatable
diseases.
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